Clinical Study

Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study

Paolo Cassano,1 Cristina Cusin,1 David Mischoulon,1 Michael R. Hamblin,2 Luis De Taboada,3 Angela Pisoni,1 Trina Chang,1 Albert Yeung,1 Dawn F. Ionescu,1 Samuel R. Petrie,1 Andrew A. Nierenberg,1 Maurizio Fava,1 and Dan V. Iosifescu1,4

1Depression Clinical & Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
2Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
3LiteCare LLC, Newark, DE 19702, USA
4Department of Psychiatry, The Mount Sinai Hospital, New York, NY 10029, USA

Correspondence should be addressed to Paolo Cassano; pcassano@mgh.harvard.edu

Received 4 May 2015; Accepted 21 July 2015

Academic Editor: Antonio Vita

Copyright © 2015 Paolo Cassano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transcranial near-infrared radiation (NIR) is an innovative treatment for major depressive disorder (MDD), but clinical evidence for its efficacy is limited. Our objective was to investigate the tolerability and efficacy of NIR in patients with MDD. We conducted a proof of concept, prospective, double-blind, randomized study of 6 sessions of NIR versus sham treatment for patients with MDD, using a crossover design. Four patients with MDD with mean age 47 ± 14 (SD) years (1 woman and 3 men) were exposed to irradiance of 700 mW/cm² and a fluence of 84 J/cm² for a total NIR energy of 2.40 J delivered per session for 6 sessions. Baseline mean HAM-D17 scores decreased from 19.8 ± 4.4 (SD) to 13 ± 5.35 (SD) after treatment (t = 7.905; df = 3; P = 0.004). Patients tolerated the treatment well without any serious adverse events. These findings confirm and extend the preliminary data on NIR as a novel intervention for patients with MDD, but further clinical trials are needed to better understand the efficacy of this new treatment. This trial is registered with ClinicalTrials.gov NCT01538199.

1. Introduction

Near-Infrared Radiation: Mechanism of Action. In experimental and animal models, laser near-infrared radiation (NIR) noninvasively delivers energy to cytochrome c oxidase and by stimulating this key mitochondrial respiratory chain enzyme (COMPLEX IV, electron transfer chain) leads to increased adenosine triphosphate (ATP) production [1–3]. While several NIR wavelengths have been shown to benefit neuronal cell cultures, the most effective ones (830 nm, 670 nm) paralleled the NIR and red action spectra of oxidized cytochrome c oxidase [4]. Data suggest that coherent red light (670 nm diode laser) protects the viability of cell culture after oxidative stress, as indicated by increased mitochondrial membrane potentials [5]. NIR also stimulates neurite outgrowth mediated by nerve growth factor, and this effect could also have positive implications for axonal protection [5]. Neuroprotective effects of incoherent red light, 670 nm light emitting diode (LED) and 630 nm narrow angle LED, have been documented in in vivo models of mitochondrial optic neuropathy [6,7]. In vivo bioenergetic changes with coherent NIR (810 nm diode laser) were observed at McLean Hospital (Belmont, MA) in beagle dogs, where a shift towards greater bioenergetic efficiency (PCr/β-NTP ratio) occurred in the anterior cingulate cortex after transcranial NIR exposure (3 times/week for 2 weeks) (Mintzopoulos et al., unpublished). In animal models of traumatic brain injury (TBI), coherent NIR (810 nm diode laser) appears to be an effective treatment [8–10] and improves neurogenesis [11]. In addition, incoherent NIR exposure (1072 nm LED) has been shown to improve memory performance in middle-aged mice [12].

Near-Infrared Radiation for Depression and Cognition. In a double-blind randomized study in healthy volunteers, exposure to coherent NIR (1064 nm laser) significantly improved overall affect, sustained attention, and visual memory [13].
A report of two individual cases and a case series of eleven patients with TBI suggested that exposure to incoherent NIR and red light (870 nm/633 nm LEDs) positively affected sustained attention, memory and executive functions, and self-awareness, self-regulation, sleep, and depressed mood [14, 15]. These benefits in TBI patients were confirmed in a cohort of ten, treated with coherent NIR light (810 nm/980 nm laser) [16]. A preliminary open study in ten depressed subjects has shown that NIR (810 nm LED) may be effective and well tolerated for depression and anxiety despite a history of treatment resistance [17].

Our pilot study aimed at confirming and extending these findings by including a 31P-MRS assessment of brain metabolism, as well as safety and efficacy data on repeated administrations of transcranial NIR with a high power laser diode. As an explanatory note to the readers, the authors would like to clarify the circumstances under which our controlled clinical trial (https://www.clinicaltrials.gov/: NCT01538199) only yielded preliminary uncontrolled data on repeated NIR sessions for MDD. The present study was in fact prematurely interrupted by its sponsor, the PhotoThera Inc. PhotoThera had largely invested in three clinical trials (NEST 1, NEST 2, and NEST 3), testing the same NIR device (NeuroThera Laser) used in our study for the treatment of ischemic stroke. NEST 3, the largest of the NEST trials, was stopped due to an interim analysis revealing futility [18]. PhotoThera, financed by venture capitalists, revoked the funding for all its clinical trials, including investigator initiated studies such as ours. PhotoThera closed down in October 2012 and filed for bankruptcy in May 2013.

2. Methods

This single-site study was approved by the Massachusetts General Hospital (MGH) institutional review board (IRB); the Food and Drug Administration (FDA) confirmed that an Investigational Device Exemption (IDE) was not required, as the investigation entailed nonsignificant risks. The Harvard Psychiatry Department (Dupont-Warren Fellowship and Livingston Award), the Brain and Behavior Research Foundation (NARSAD Young Investigator Award), and PhotoThera Inc. sponsored this investigation. Subjects meeting the Diagnostic Statistical Manual-IV (DSM-IV) criteria for MDD, with at least moderate depression (Hamilton depression rating scale, HAM-D17 total score between 14 and 24), were included in the study after providing informed consent. Subjects had failed at most one antidepressant medication and psychotherapy course (stable treatment for at least 6 and 8 weeks, resp.) during the current episode. Active substance use disorders (within prior 6 months), lifetime psychotic episodes, unstable medical illness, and active suicidal or homicidal ideation were exclusionary criteria. Subjects with head-implants, taking light-activated drugs, or having forehead skin conditions (e.g., rash or tattoo) were also excluded. In addition, subjects with implanted metal devices, severe claustrophobia, or weight above 275 lbs were excluded for MRI contraindications. Subjects were randomized to a 7-week double-blind sham-controlled treatment, involving three weeks of either NIR or sham exposures twice a week followed by crossover to three more weeks of the alternate exposure; that is, patients that were exposed to NIR during the first three weeks of the study were exposed to sham, after a washout week, and vice versa. At each treatment session, NIR light (NeuroThera, continuously emitting GaAlAs-laser, manufactured by PhotoThera Inc., with 808 ± 10 nm wavelength (or the same device acting as a sham), with active cooling, total power output 5 W, and verified with a power meter attached to a photodiode detector, Ophir NOVA, prior to the experimental sessions) was administered to the forehead bilaterally at four sites total (2 min per site, 3.3 cm lens piece aperture, 3 cm spot diameter, and 71 cm² spot area). We decided to cover the forehead widely (4 sites) to extensively irradiate the prefrontal cortex without overlaps; the data on safety from the NEST 1, NEST 2, and NEST 3 studies on stroke for our same instrument showed that irradiation of up to 20 sites on the scalp was safe (2 min each) [18–21]. Our parameters (including the localization to the forehead) were somewhat consistent with those of Schiffer and colleagues [17], which had demonstrated clinical efficacy of a single session of NIR in depression. NIR was administered with an irradiance of approximately 700 mW/cm² and a fluence of 84 J/cm² (same parameters as in NEST 1, NEST 2, and NEST 3) for a total NIR energy of 2.40 kJ delivered per session with the devices’ actively cooled sapphire output lens in direct skin contact. See Table 1 for a summary of the NIR parameters used for this study and comparative studies of transcranial laser therapy (TLT). See Figure 1 for the picture of the handheld portion of the NeuroThera device. No additional information was provided by the manufacturer.

The NeuroThera device was programmed with a list of subjects’ treatment codes randomly assigning patients to either NIR or sham exposure for the first three weeks of the crossover study; the device program kept track of the initial assignment and switched the patient’s exposure, NIR to sham and vice versa, for the second three weeks of the study treatment. Since the study from Schiffer and colleagues [17] demonstrated that one treatment with NIR was insufficient...
Table 1: Summary of the NIR parameters used for this study (Cassano et al.) and other comparison studies.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pilot, open</td>
<td>Open</td>
<td>Double-blind randomized NIR versus sham</td>
<td>Open</td>
</tr>
<tr>
<td>Subjects enrolled</td>
<td>4 MDD completers</td>
<td>10 resistant MDD</td>
<td>40 psychology undergraduates</td>
<td>11 chronic TBI (8 cases with depression; 5 with at least moderate severity)</td>
</tr>
<tr>
<td>Number of treatment sessions</td>
<td>2/week for 3 weeks</td>
<td>1</td>
<td>1</td>
<td>3/week for 6 weeks</td>
</tr>
<tr>
<td>Duration of clinical follow-up</td>
<td>8 weeks</td>
<td>4 weeks</td>
<td>2 weeks</td>
<td>14 weeks</td>
</tr>
<tr>
<td>Clinical outcome(s)</td>
<td>50% remission of MDD at weeks 6-7 (HAM-D$_{17} \leq 7$)</td>
<td>60% remission of MDD at week 2 (HAM-D-21 &lt;10)</td>
<td>Maintained positive affect at 2 weeks compared to decline of control group (PANAS)</td>
<td>37% response of depression at week 7 (decrease of BDI-II total score ≥50% from baseline)</td>
</tr>
<tr>
<td>Device specifications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manufacturer/model/type</td>
<td>PhotoThera/NeuroThera/laser diode</td>
<td>Custom device/Marubeni America Corp./LED</td>
<td>Cell Gen Therapeutics/Model CG-5000/laser diode</td>
<td>MedX Health/Model 1100/LED</td>
</tr>
<tr>
<td>Wavelength (nm)</td>
<td>808</td>
<td>810</td>
<td>1064</td>
<td>870 and 633</td>
</tr>
<tr>
<td>Spot diameter (cm)</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>5.35</td>
</tr>
<tr>
<td>Spot area (cm$^2$)</td>
<td>71</td>
<td>~1</td>
<td>12.6</td>
<td>22.5</td>
</tr>
<tr>
<td>Site exposure parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time (sec)</td>
<td>120</td>
<td>240</td>
<td>240</td>
<td>585</td>
</tr>
<tr>
<td>Irradiance (mW/cm$^2$)</td>
<td>700</td>
<td>250</td>
<td>250</td>
<td>22.2</td>
</tr>
<tr>
<td>Fluence (J/cm$^2$)</td>
<td>84</td>
<td>60</td>
<td>60</td>
<td>13</td>
</tr>
<tr>
<td>Treatment exposure parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of exposed sites</td>
<td>Four</td>
<td>Two</td>
<td>Two</td>
<td>Eleven</td>
</tr>
<tr>
<td>Site locations, transcranial treatments</td>
<td>Bilateral (R and L forehead center at 20 and 40 mm from sagittal line)</td>
<td>Bilateral (R and L forehead at EEG map sites: F3, F4)</td>
<td>Unilateral (R, frontal pole on 4 cm medial and lateral)</td>
<td>Midline and bilateral (forehead (prefrontal) and temporal, parietal, and occipital area)</td>
</tr>
<tr>
<td>Total area exposed (&quot;treatment window,&quot; cm$^2$)</td>
<td>28.4 (21 × 4 sites)</td>
<td>2 (1 × 2 sites)</td>
<td>25.2 (12.6 × 2 sites)</td>
<td>247 (22.5 × 11 sites)</td>
</tr>
<tr>
<td>Total energy delivered, per session (kJ)</td>
<td>14.4 (total energy per session × 2 sessions/week × 3 weeks)</td>
<td>0.12 (total energy per session × 1 session)</td>
<td>1.51 (total energy per session × 1 session)</td>
<td>57.87 (total energy per session × 3 sessions/week × 6 weeks)</td>
</tr>
</tbody>
</table>
to determine a durable antidepressant response, we then
decided to deliver a course of 6 treatments within 3 weeks.
The relatively short timeframe of 3 weeks was decided to allow
crossover within an overall 8-week length of trial. The double-
blinding was ensured by carrying out identical procedures,
identical device interface, including prompts and sounds, and
actively cooling the skin surface at the treatment area during
both NIR and sham exposures. PhotoThera Inc., the company
that manufactured the device, produced data showing that
active cooling of the sapphire lenses ensured blinding by
preventing skin warming. A specific semistructured scale, the
Transcranial Light Therapy Self-Report Questionnaire (T-SR-
Q) was completed by participants after the first 6 sessions. The
scale explored any discomfort and inconvenience related to
the treatment sessions, to detect potential unblinding due to
warming effect or to other phenomena. None of the subjects
reported skin warming (on the contrary one reported exces-
sive cooling), which validated our blinding. The NIR light is
otherwise invisible. All subjects remained on stable anti-de-
pressant treatment during the trial. There were no restrictions
on class of concomitant antidepressant medications or other
concomitant medications, except for photosensitive medicina
tions which were exclusionary. Tolerability was assessed with
the Systematic Assessment for Treatment Emergent Events
(SAFTEE) scale [22]. The primary outcome measures were
both change in depressive symptoms (HAM-D17) at endpoint
and remission from depressive symptoms, defined as HAM-
D17 ≤ 7. A recent assessment of the interrater reliability
among clinicians at our group (MGH Depression Clinical and
Research Program) in diagnosing MDD and in measuring
interrater reliability was established through
live, independent interviews of patients with the use of the
HAM-D and SCID-I/P, indicating satisfactory agreement.

We present analysis of four subjects from a sample of eight
adults who met study criteria and were initially enrolled in
the study. The four subjects excluded from analysis either did
not complete the study or, upon review of final study results,
failed to meet the study’s inclusion/exclusion criteria. One
subject dropped out before the first treatment session and
two shortly after the first session. These patients could not
commit to the full treatment course. One of the patients that
dropped out after the first treatment session experienced a
headache and left hand paresthesias during the MRS scan,
possibly related to preexisting carpal tunnel syndrome. Upon
unblinding the device’s preprogrammed treatment codes, it
was determined that none of the dropouts received active
NIR. Data from one more subject were subsequently excluded
as her urine repeatedly tested positive for cannabinoids. This
latter subject’s exclusion was based on her meeting criteria
for substance use disorder, which was determined towards
the end of her participation. The unblinded treatment codes
also showed that all four subjects who completed the 7-week
treatment phase and were analyzed received NIR exposures
in their first 3 weeks. By means of a paired t-test we tested the
significance of the change in the mean HAM-D17 total score
(from baseline) to week 8. Although the primary comparison
was with the last assessment (week 8), exploratory analyses
were conducted for change from baseline to weeks 4, 5, 6,
and 7. A last observation carried forward (LOCF) was also
performed to account for one missing value at week 8. We
decided not to present the available 31P-MRS data since
our lack of adequate comparison and our small sample size
limited scientific inferences.

3. Results

The four completers had a mean age of 47 ± 14 (SD) years
(1 woman and 3 men). Their length of depressive episode
was at least 18 months. Baseline HAM-D17 scores averaged
19.75 ± 4.35 (SD). None of them was taking antidepressant
medications at the time of the trial and only one was receiving
(long-standing) counseling; however, the counseling was not
a proven effective form of psychotherapy for major depres-
sive disorder, such as cognitive behavioral therapy (CBT)
or interpersonal therapy (IPT). None of the four subjects
failed to respond to an evidence-based treatment or
FDA-approved treatment for depression during the current
depressive episode. During the course of the trial, none of the
participants started an antidepressant treatment.

Two of the four treatment-completers (50%) achieved
remission (albeit not sustained) with HAM-D17 ≤ 4 and
3 at weeks 6 and 7, respectively. The mean HAM-D17 total
score (n = 3) decreased from 17.7 ± 1.53 (SD) at baseline
to 10.3 ± 0.57 (SD) at week 8 (t = 8.315; df = 2; P = 0.014). On the LOCF analysis, accounting for one missing
value at week 8, the mean HAM-D17 total score (n = 4)
decreased from 19.75 ± 4.35 (SD) to 13 ± 5.35 (SD) (t = 7.905; df = 3; P = 0.004). Figure 2 illustrates the mean
HAM-D17 total scores over the course of the study for the
four subjects. The NIR treatment was well tolerated with
no adverse events; only one subject, already diagnosed with
irritable bowel syndrome, reported transient, mild diarrhea,
which was deemed unrelated to study treatment.

4. Discussion

We report findings on the safety and efficacy of multiple
NIR sessions in patients with MDD. We observed, in four
MDD subjects, that posttreatment depression ratings were
significantly reduced from baseline, and the treatment was
well tolerated.

Time to remission was 6-7 weeks, consistent with other
antidepressant treatments. Since all four subjects who com-
pleted the 7-week treatment phase received NIR in their first
3 weeks (Figure 2), a carry-over effect from NIR is likely.
In two prior reports, significant clinical and psychological
effects were reported as early as week 2, after only a single
NIR treatment [13, 17]. A possible explanation for this time to
response discrepancy is that NIR in our study was delivered
at higher irradiance (700 mW/cm2) and fluence (84 J/cm2)
(Table 1). Alternatively, twice-weekly NIR sessions at four
sites for 3 weeks might be suboptimal. A paradoxical dose-
response, where higher power and energy densities might
be less effective, has been postulated for NIR. Based on
animal data, Xuan and colleagues [11] have postulated that
an excessive exposure to NIR might be in fact counterproductive. This is somewhat in contrast with other reports in TBI patients, where daily NIR sessions appeared to be beneficial for cognition, although at a much lower NIR fluence (13–20 J/cm²) [14, 15]. See Table 1 for the report of eleven cases from Naeser and colleagues [15].

Our 50% treatment remission rate (albeit not sustained) in this small sample size is consistent with the 60% remission rate reported in subjects with resistant MDD treated with NIR by Schiffer and colleagues [17]. Similar to Schiffer and colleagues [17], we used an augmentation design in which NIR was added to stable (at least 6 weeks) treatment. However, because none of our 4 subjects was taking antidepressant medications, we cannot ascribe the high remission rates to synergism. In contrast to Schiffer and colleagues [17], who used incoherent NIR (810 nm), our pilot was conducted with a laser device, coherent NIR. While coherent light (lasers) is likely to achieve deeper penetration into brain tissue [23], we did not observe any apparent advantage by comparing response rates in both studies.

The most important result of this pilot study on repeated NIR treatment is its tolerability and safety in patients with MDD. Our report is the first systematic assessment of tolerability and safety of repeated administration of transcranial NIR with a 5 W laser with high irradiance (700 mW/cm²) in depressed subjects. Our finding is consistent with prior case-reports and case series suggesting that multiple transcranial NIR administrations could be safe in TBI subjects [14–16]. We encountered only one potential adverse event characterized by transient and mild diarrhea in a subject with irritable bowel syndrome. This event was attributed to the subject’s preexisting medical illness and considered unrelated to the NIR treatment; it resolved within a week and did not require study discontinuation or other interventions. Consistent with our results, several large NIR stroke studies have shown no significant difference in rates of adverse events or serious adverse events between NIR and sham [18, 24].

5. Conclusions

Our findings are limited by our small sample size and by a probable carry-over effect. However, they support the hypothesis that TLT could be an effective treatment for MDD. If subsequent studies confirm that a brief course of TLT is effective for treating MDD, this intervention could have advantages over monotherapy with standard antidepressant medications because TLT is noninvasive, has few side effects, and might not require long-term administration. TLT and other treatments targeting brain mitochondria represent an innovative class of therapeutics (compared to standard antidepressant treatment) for patients with MDD.

Disclosure

This study was presented on October 25, 2013, at the 2013 New York Annual Symposium of the Brain and Behavior Research Foundation. This was an investigator initiated study; PhotoThera Inc. did not design the study per se (Dr. Maurizio Fava suggested the study design), but it contributed to the definition of imaging outcome variables that are not presented in this paper. The Brain and Behavior Research Foundation and the Dupont-Warren Committee at the Harvard Psychiatry Department did not contribute in any way to the design of the study. None of the funders had any input in the collection, analysis, and interpretation of the data. Dr. Luis De Taboada (ex-PhotoThera) joined as an author when the paper was nearly completed and reviewed the specifications of the instrument described in the paper.

Conflict of Interests

Dr. Paolo Cassano’s salary was supported by the Harvard Psychiatry Department (Dupont-Warren Fellowship and Livingston Award), by the Brain and Behavior Research Foundation (NARSAD Young Investigator Award), and by
the PhotoThera Inc, unrestricted grant. Drug donation was from TEVA. Travel reimbursement was from Pharmacia-Upjohn. Dr. Cristina Cusin's salary is supported by NIMH (R21 MH 095826-01), grant from the American Suicide Prevention Foundation and Department of Defense (V-SUBMGH-I-1-40, W81XWH-I-1-0073). Disclosures regarding financial relationships with commercial entities are as follows: Dr. Michael Hamblin participated in only one session (12/17/13) of the DSMB for the ELATED study, which occurred after completion of the data collection for the same study. Research grants and consulting fees are from PhotoThera Inc. Scientific Advisory Board of TransferMall Cap Inc. (LLLT for hair regrowth). Michael R. Hamblin was supported by US NIH Grant R01AI050875. Disclosures regarding financial relationships with commercial entities are as follows: Mr. Luis De Taboada designed and developed the NeuroThera systems used for the study and received salary from PhotoThera Inc. as VP of Research and Development during a portion of this study. Mr. Luis De Taboada receives salary from LiteCure LLC (Newark, DE) as VP of research and development. Disclosures regarding patents are as follows: Mr. Luis De Taboada is a named inventor in multiple patents for the treatment of neurological disorders and injuries, including MDD. Ms. Angela Pisoni, Dr. Trina Chang, Dr. Albert Yeung, Dr. Dawn F. Ionescu, and Mr. Samuel R. Petrie have no conflict of interests to report regarding the publication of this paper. Dr. Andrew A. Nierenberg is a consultant for the Abbott Laboratories, American Psychiatric Association, Appliance Computing Inc. (Mindsite), Basilea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaiance, Genentech, GlaxoSmithKline, Hoffman-LaRoche, Infomedic, Lundbeck, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Parexel, Pfizer, PGX Health, Ridge Diagnostics Schir, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva, consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc., Dainippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGX Health, Shire, Schering-Plough, Targacept, and Takeda/Lundbeck Pharmaceuticals. He receives grant/research support from American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonetics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceuticals, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst. Honoraria include Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing and Wolters Klower Publishing ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova Southeastern University, NAMI, Institute of Medicine, CME Institute, and ISCTM. He was currently or formerly on the advisory boards of Appliance Computing, Inc., Brain Cells, Inc., Eli Lilly and Company, Genentech, Johnson and Johnson, Takeda/Lundbeck, Targacept, and InfoMedic. He owns stock options in Appliance Computing, Inc., Brain Cells, Inc., and Medavante and has copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI). Dr. Fava received research support from the following for-profit and nonprofit private entities: Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Covance; Covidiem; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganedens Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Medavante; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates, Inc.; Pharmavite LLC; PharmRx Therapeutics; PhotoThera; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories; advisory/consulting: Abbott Laboratories; Afectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoseSearch Life Sciences.
received research support from Aspect Medical Systems, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharma Solutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neurovention, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC; Pfizer Inc.; PharmaStar; Pharmavite LLC; PharmoRx Therapeutics; Precision Human Biobulary; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Pslyn Neurosciences, Inc.; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; additional conflict of interests might arise for Dr. Fava from compensation related to speaking and publishing; he received compensations from the following entities: Adamed, Co.; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories; Dr. Fava holds patents and equities related to Compellis; PsyBrain, Inc. Royalty/patent, another income: Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of ketamine plus scopolamine in Major Depressive Disorder (MDD). Dr. Fava owns copyrights in connection to the following publications: the MGH Cognitive and Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SHI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs and Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte. Ltd. In the last three years Dan V. Iosifescu has been a consultant for CNS Response, Otsuka, Servier, and Sunovion and has received research support through Mount Sinai from AstraZeneca, Brainway, Euthymics, Neosync, Roche, and Shire. Dr. Iosifescu’s lifetime conflict of interests is detailed hereafter: he has received research support from Aspect Medical Systems, Forest Laboratories, and Janssen Pharmaceutical, he has been a consultant for Forest Laboratories, Gerson Lehrman Group, and Pfizer, Inc., and he has received speaking honoraria from Eli Lilly & Co., Forest Laboratories, Pfizer, Inc., and Reed-Elsevier.

**Authors’ Contribution**

Paolo Cassano conceived the study, conducted the study, evaluated study subjects, delivered treatment, and wrote first draft of paper for depression. Cristina Cusin evaluated study subjects, delivered treatment, and reviewed paper for depression. David Mischoulon evaluated study subjects, delivered treatment, and reviewed paper for depression. Michael R. Hamblin reviewed paper for transcranial light therapy. Luis De Taboada reviewed paper for instrument specifications. Angela Pisoni assisted with subjects management during the study and preparation of tables, figures, references, and editing of paper. Trina Chang evaluated study subjects, delivered treatment, and reviewed paper for depression. Albert Yeung evaluated study subjects, delivered treatment, and reviewed paper for depression. Dawn F. Ionescu reviewed paper for depression. Samuel R. Petrie assisted with preparation of tables, figures, references, and editing of paper. Andrew A. Nierenberg reviewed paper with specific focus on presenting data in abbreviated format. Maurizio Fava contributed to the conception of the study. Dan V. Iosifescu contributed to the conception of the study and to the writing of the first draft. All authors have approved the final version of the paper.

**Acknowledgments**

The authors thank Dr. Marc J. Kaufman and Dr. Fei Du from the McLean Imaging Center, McLean Hospital, who kindly supervised Dr. Paolo Cassano and performed the MRS scans on the study subjects, respectively, and Dr. Clark E. Tedford from LumiThera Inc. who provided them with the training for the use of the PhotoThera devices. The Harvard Psychiatry Department (Dupont-Warren Fellowship and Livingston Award), the Brain and Behavior Research Foundation (NARSAD Young Investigator Award), and PhotoThera Inc. sponsored this investigation.

**References**


